Rockwell Medical (NASDAQ:RMTI) Upgraded at Zacks Research

Zacks Research upgraded shares of Rockwell Medical (NASDAQ:RMTI) from a strong sell rating to a hold rating in a report issued on Thursday morning,Zacks reports.

Other equities research analysts also recently issued reports about the company. Wall Street Zen raised Rockwell Medical to a “hold” rating in a research report on Saturday, July 25th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Rockwell Medical in a report on Friday, September 11th. Finally, Weiss Ratings upgraded Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $20.00.

Rockwell Medical Stock Performance

Shares of NASDAQ:RMTI traded down $0.35 on Thursday, hitting $7.03. 42,451 shares of the company were exchanged, compared to its average volume of 24,348. The company’s 50 day moving average price is $7.80 and its two-hundred day moving average price is $8.07. Rockwell Medical has a one year low of $4.89 and a one year high of $12.90. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.00 and a current ratio of 3.25. The firm has a market capitalization of $28.33 million, a price-to-earnings ratio of -4.92 and a beta of 1.75.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.41). Rockwell Medical had a negative net margin of 7.79% and a negative return on equity of 15.72%. The company had revenue of $19.12 million for the quarter, compared to analyst estimates of $18.22 million. Research analysts expect that Rockwell Medical will post -0.90 earnings per share for the current year.

Institutional Investors Weigh In On Rockwell Medical

A hedge fund recently raised its stake in Rockwell Medical stock. Renaissance Technologies LLC raised its holdings in Rockwell Medical, Inc. (NASDAQ:RMTI) by 36.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 639,120 shares of the company’s stock after buying an additional 170,800 shares during the quarter. Renaissance Technologies LLC owned 1.62% of Rockwell Medical worth $571,000 as of its most recent SEC filing. 23.31% of the stock is owned by institutional investors.

Rockwell Medical News Summary

Investors following RMTI have been watching these news items:

• Positive Sentiment: The proposed acquisition of Vantive’s hemodialysis products and related business could substantially expand Rockwell Medical’s scale. Management expects the combined company to generate $400 million to $450 million in annual revenue and targets closing in mid-2027. Combined revenue outlook and Vantive closing target
• Negative Sentiment: The quarterly loss was $0.59 per share, substantially wider than the $0.18 loss analysts expected and the $0.50 loss a year earlier. The earnings miss may offset the stronger sales figures. Quarterly loss and revenue results
• Negative Sentiment: Regulatory approvals for the Vantive transaction could bring costly conditions and reduce expected synergies, creating uncertainty around the deal’s benefits and timeline. Regulatory risks around the Vantive transaction

Rockwell Medical Company Profile

Rockwell Medical, Inc. is a healthcare company that develops, manufactures and distributes products used in the treatment of people with kidney disease, particularly patients receiving hemodialysis. Its offerings include acid and bicarbonate concentrates used to prepare dialysis solutions, as well as related supplies and services for dialysis providers. The company has also developed pharmaceutical products for use in dialysis care. Founded in 1996, Rockwell Medical is based in the United States and serves dialysis providers in the U.S. and select international markets.